What is EPIRUS Biopharmaceuticals 6-1 Month Momentum %?
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-29), EPIRUS Biopharmaceuticals's 6-1 Month Momentum % is -90.00%.
The industry rank for EPIRUS Biopharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:
EPRSQ's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -5.095
vs EPRSQ: -90.00
Competitive Comparison of EPIRUS Biopharmaceuticals's 6-1 Month Momentum %
For the Biotechnology subindustry, EPIRUS Biopharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EPIRUS Biopharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EPIRUS Biopharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where EPIRUS Biopharmaceuticals's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
EPIRUS Biopharmaceuticals 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of EPIRUS Biopharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
EPIRUS Biopharmaceuticals (EPIRUS Biopharmaceuticals) Business Description
EPIRUS Biopharmaceuticals Inc is a global biopharmaceutical company focused on building biosimilar business targeting rare diseases by improving patient access through cost-effective medicines. The product candidates of the company are BOW080 for the potential treatment of ultra-rare blood disorders and BOW070 for the potential treatment of an uncommon lymphoproliferative disorder known as Castleman's disease. The group generally operates through the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EPRSQ has been successfully added to your